MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
GlobeNewswire · 财报与经营业绩 · November 11, 2026 at 7:30 AM ET
Read the full report at the original publisher.